New Ingredients, New Life For Cytodyne’s Weight Loss Supplements
A firm that has agreed to pay as much as $12.8 million to settle a false advertising complaint and that reorganized under bankruptcy protection after incurring losses from ephedra-related lawsuits is returning to the marketplace with a new weight loss supplement, according to a Jan. 15 announcement
More from Archive
More from Pink Sheet
Madrigal Pharmaceuticals’ resmetirom could become the first approved treatment for non-cirrhotic metabolic dysfunction-associated steatohepatitis in the EU, if the European Medicines Agency issues a positive opinion for the drug later this week.
Center for Biologics Evaluation and Research Director Vinay Prasad said Commissioner Martin Makary wants to release previously inaccessible FDA documents, but previous commissioners have made the same pronouncements only to make little progress.
The Pediatric Advisory Committee will review postmarketing safety for three vaccines and the oncologic drugs panel will consider the return of GSK’s belantamab mafodotin. An FDA notice about a 30 July meeting on Capricor’s deramiocel for Duchenne muscular dystrophy was withdrawn.